Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Yuliang Zhao, Ph.D.

Yuliang Zhao, Ph.D. 

Yuliang Zhao, Ph.D.

Yuliang Zhao, Ph.D.

Senior Affiliate Member
The Methodist Hospital Research Institute
Director, CAS Key Lab for Biomedical Effects of Nanomaterials & Nanosafety
Institute of High Energy Physics
Chinese Academy of Sciences
National Center for Nanoscience and Technology, China
Director, Research Center for Cancer Nanotechnology
Tianjin Cancer Hospital
E-mail: zhaoyuliang@ihep.ac.cn
Phone: +86-10-8823-3191


B.S.   Sichuan University, Sichuan, China
Ph.D.   Tokyo Metropolitan University, Tokyo, Japan

Postdoctoral Training

Postdoctoral Fellow, Japan Society for the Promotion of Science, Tokyo Metropolitan University, Japan (Chemistry)



Dr. Yuliang Zhao earned his Ph.D. in Chemical Science from the Tokyo Metropolitan University in 1999. He held faculty appointments at the Chinese Academy of Sciences in Beijing before becoming a member of The Methodist Hospital Research Institute in 2011. Dr. Zhao also holds adjunct faculty appointments at Peking University (Beijing), the Medical School of Jilin University (Changchun), and Sichuan University (Chengdu).

As the the founder and Director of CAS Key Lab for Biomedical Effects of Nanomaterials & Nanosafety, he directs a research program that is developing a new generation of cancer chemotherapeutics using low-toxic nanoparticles. Dr. Zhao has also been a member of nine study sections and review boards in China and Europe. He is the founder and Director of Research Center for Cancer Nanotechnology at Tianjin Cancer Hospital in China. He has served as the Associate Editor and editorial board member of seven scientific research journals since 2006.

Description of Research

Dr. Zhao's research program focuses on nanotoxicology, cancer nanotechnology, and nanochemistry. He is developing molecular dynamics modeling for designing low-toxic nanosurfaces for cancer nanotechnology applications, and for lowering the toxicity of nanomaterials in living systems. A major aim of his research is to understand the mechanisms of nanotoxicity of engineered nanoparticles in vivo. In addition, a major research goal is to characterize the structure-function relationships between the tumor microenvironment (like extracellular matrices) and engineered nanoparticles that inhibit tumor growth and metastasis. Dr. Zhao's research team at CAS collaborates with Dr. Mauro Ferrari, Dr. Ye "Tony" Hu and other faculty members of the Department of Nanomedicine at TMHRI in the research of cancer nanotechnology and nanotechnology based biomarker identification.

Major Areas of Research

Nanotoxicology, cancer nanotechnology, chemistry, nanoscale molecular dynamics modeling

Recent Publications

Jia L, Zhao YL, Liang XJ. Fast evolving nanotechnology and relevant programs and entities in China. Nano Today. 2011;6(1):6-11.

Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7449-54.

Wang M, Feng WY, Zhao YL, Chai ZF. ICP-MS-based strategies for protein quantification. Mass Spectrom Rev. 2010 Mar-Apr;29(2):326-48.

Gao X, Zhang SB, Zhao Y, Nagase S. A nanoscale jigsaw-puzzle approach to large pi-conjugated systems. Angew Chem Int Ed Engl. 2010 Sep 10;49(38):6764-7.

Wang L, Liu Y, Li W, Jiang X, Ji Y, Wu X, Xu L, Qiu Y, Zhao K, Wei T, Li Y, Zhao Y, Chen C. Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano Lett. 2011 Feb 9;11(2):772-80.


Chinese Academy of Sciences profile